Northwestern Health Sciences University

EVOLVE BIOSYSTEMS: STUDY DEMONSTRATES NOVEL BIOCHEMICAL MECHANISM OF NECROTIZING ENTEROCOLITIS (NEC), A LEADING CAUSE OF PREMATURE MORBIDITY AND MORTALITY

Retrieved on: 
Tuesday, August 23, 2022
Manna, Inflammation, Bifidobacterium longum, Cargill, Metabolomics, Klebsiella pneumoniae, University, CEO, Technology, Perforation, Birth weight, Bill, Lists of diseases, Research, Proteobacteria, Physiology, Metagenomics, Doctor of Philosophy, Associate, Disease, Death, Nutrient, Northwestern Health Sciences University, OHSU, Incidence, Oregon Health & Science University, Bill & Melinda Gates Foundation, Food, Infant, Multimedia, Tate, Veni, vidi, vici, Klebsiella, Enterobacter cloacae, Peritonitis, Horizons Ventures, Breast milk, Biochemistry, Sepsis, NEC, Risk, Dose, Fermentation, Dysbiosis, Necrosis, Growth, Metabolism, Health, Late preterm infant, University of California, Davis, Patient, Necrotizing enterocolitis, Pharmaceutical industry, Dietary supplement, Birth control, Frontiers, MD, Pediatrics, Enterobacteriaceae

DAVIS, Calif., Aug. 23, 2022 /PRNewswire/ -- Results of a study published today in Frontiers in Pediatrics have revealed critical missing information linking potentially pathogenic gut microbes to intestinal injury and necrotizing enterocolitis (NEC). NEC is one of the leading causes of death and disease in premature newborns. Although studied for decades, the precise cause of NEC remains undefined. This new study heralds a novel understanding of NEC and provides the rationale for potential prevention strategies.

Key Points: 
  • This new study heralds a novel understanding of NEC and provides the rationale for potential prevention strategies.
  • In severe cases, this injury extends through the intestinal wall leading to irreversible tissue death and perforation.
  • In the study published today, researchers combined metagenomics and targeted metabolomics with functional in vivo and in vitro assessment to define a novel molecular mechanism of NEC.
  • Metabolic Model of Necrotizing Enterocolitis in the Premature Newborn Gut Resulting from Enteric Dysbiosis.

Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
Oregon Health & Science University, U.S. Securities and Exchange Commission, SYK, Risk, Forward-looking statement, GLOBE, Gene expression, Private Securities Litigation Reform Act, SEC, Investment, Cancer, Clinical trial, PDX, Research, Security (finance), AML, CDK9, Patient, European Hematology Association, Bone marrow, FLT3, SAN, D, Therapy, NPM1, MYC, Mutation, Nasdaq, LinkedIn, Northwestern Health Sciences University, Cytarabine, KRON, Pharmaceutical industry, Lease, Kronos

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today reported recent business progress and second-quarter 2022 financial results.

Key Points: 
  • Data are anticipated in the second half of 2023 with a primary endpoint of measurable residual disease negative complete response.
  • Kronos Bio opened additional sites for its planned Phase 1b/2 clinical trial of lanraplenib, the companys next generation SYK inhibitor, in combination with gilteritinib in patients with FLT3-mutated AML.
  • Kronos Bio is continuing to enroll patients in the dose escalation stage of the Phase 1/2 study of KB-0742 in solid tumors.
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

Retrieved on: 
Tuesday, August 2, 2022
Research, Hospitals, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Congress, Emory University, Oregon Health & Science University, Twitter, Food, EHA, ALL, Transplant, Risk, ASH, Toxic epidermal necrolysis, Ronald Reagan UCLA Medical Center, City, Immune system, Safety, Cancer, Northwestern Health Sciences University, European Hematology Association, Quality of life, Stanford School, Â, AML, Lymphatic system, Patient, Acute leukemia, Sarah Cannon Research Institute, Blood, Graft-versus-host disease, Winship Cancer Institute, Degenerative disease, Acute myeloid leukemia, Bio, MDS, Criticism of the Food and Drug Administration, Society, GRFS, Medicine, Pharmaceutical industry, Vaccine

The primary endpoint of the Precision-T study is the rate of moderate-to-severe chronic GvHD-free survival.

Key Points: 
  • The primary endpoint of the Precision-T study is the rate of moderate-to-severe chronic GvHD-free survival.
  • The randomized Phase 3 trial is being conducted concurrently with Orca Bio's ongoing single-arm Phase 1b trial of Orca-T.
  • Orca Bio is a late-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders.
  • At Orca Bio, we hope to not only replace patients' blood and immune systems with healthy ones, but restore their quality of life.

Minnesota-based, Westridge Trading, LLC, Finds Cost Savings and White Glove Service by Leveraging Bluebird Quad Cities Data Center

Retrieved on: 
Wednesday, July 6, 2022
Data Management, Technology, Security, Other Technology, Satellite, Telecommunications, Software, Networks, Internet, Mobile, Wireless, Hardware, Efficiency, Patient, Senior, PR, Internet, Pop, Growth, IA, Northwestern Health Sciences University, ID, LLC, Communication, Westridge, City, Quad Cities, Network, Internet service provider, Pharmaceutical industry, Security printing, Bluebird

Following a referral from a colleague, Johnson took a trip to Bettendorf, IA for a tour of the Bluebird Quad Cities Data Center and soon became another happy customer.

Key Points: 
  • Following a referral from a colleague, Johnson took a trip to Bettendorf, IA for a tour of the Bluebird Quad Cities Data Center and soon became another happy customer.
  • Bluebird works really hard to ensure customers are satisfied and things are taken care of in a timely manner, said Johnson.
  • Johnson said the cost savings from Bluebirds clean and reliable power cut electrical charges in half, but that wasnt the only reason Johnson brought his business to Bluebird.
  • Bluebird owns two data centers: an underground facility in Springfield, MO, and a facility in the Quad Cities.

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

Retrieved on: 
Wednesday, June 8, 2022
ENDO, Hierarchy, Adult, Northwestern Health Sciences University, Disease, Octreotide, Maintenance, Neurosurgery, Endocrine system, FACE, 2021 Essex County Council election, Patient, Safety, GH, Union, Oregon Health & Science University, RCT, Oregon Health Plan, Degenerative disease, Pharmaceutical industry, Acromegaly

The conference will be held virtually and in person from June 11-14, 2022 in Atlanta, Georgia.

Key Points: 
  • The conference will be held virtually and in person from June 11-14, 2022 in Atlanta, Georgia.
  • The MPOWERED trial was a global, randomized, open-label and active-controlled, 15-month trial intended to support approval of Mycapssa in the European Union.
  • These patients were then followed for an additional nine months in the randomized controlled treatment (RCT) phase.
  • At the end of the RCT phase patients were provided the option to continue into an open label phase and receive Mycapssa.

Foot Levelers Momentous Endowment Creates Chair in Biomechanics and Human Performance, Supports Research, Education for Evidence-Based, Patient-Centered Outcomes

Retrieved on: 
Wednesday, May 25, 2022
Medical Devices, Medical Supplies, Women, Seniors, Men, Family, Physical Therapy, Managed Care, Consumer, Health, Work, Education, Ligament, Exercise, Pain scale, Multimedia, Science, Patient, Northwestern Health Sciences University, Pain management, Human, Solution, Quality of life, Muscle, Audio leveler, Research, Back pain, Foot Levelers, Disability, LBP, Movement, Twitter, Tendon, Spine, CEO, Pelvis, Dentistry, Health insurance, Greenawalt, Facebook, Instagram

Foot Levelers , the worlds leading provider of hand-crafted custom orthotics serving multi-disciplinary professionals and clinicians, announces a $500,000 endowment to create the Foot Levelers Chair in Biomechanics and Human Performance at Northwestern Health Sciences University, Bloomington, Minn.

Key Points: 
  • Foot Levelers , the worlds leading provider of hand-crafted custom orthotics serving multi-disciplinary professionals and clinicians, announces a $500,000 endowment to create the Foot Levelers Chair in Biomechanics and Human Performance at Northwestern Health Sciences University, Bloomington, Minn.
  • Foot Levelers, the worlds leading provider of hand-crafted custom orthotics, has been serving healthcare professionals since 1952.
  • Stabilizing orthotics help properly support the back, knees, hips, pelvis, and even neck by providing a balanced and symmetrical foundation.
  • Foot Levelers orthotics are proven to reduce LBP by 34.5%.

Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Retrieved on: 
Wednesday, May 4, 2022
ACHM, COVID-19, Drug development, Calendar, Forward-looking statement, Nasdaq, GLOBE, CNS, Company, Applied Genetic Technologies Corporation, AAV, Safety, ARVO, Research, Retina, EZ, Time, Annual report, Central nervous system disease, Patient, Achromatopsia, Association, Risk, Therapy, Association for Research in Vision and Ophthalmology, Form 10-K, Severe cognitive impairment, Neurotology, Oregon Health and Science University Center for Women's Health, Optogenetics, Northwestern Health Sciences University, Assistant, SEC, Oregon Health & Science University, Technology, Annual general meeting, Central nervous system, Pharmaceutical industry, Ophthalmology

GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the presentation of additional positive findings from the ongoing X-linked retinitis pigmentosa (XLRP) Phase 1/2 study of AGTC-501, including 18-month safety and efficacy data, at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, May 1-4, 2022 in Denver, Colorado.

Key Points: 
  • The data presented at ARVO update previously reported data from this non-randomized, open-label Phase 1/2 study that the Company believes showed both safety and biological activity of AGTC-501 12 months after treatment.
  • The 18-month data appear to show safety and efficacy signals similar to the studys 12-month findings, including improvements to the ellipsoid zone (EZ).
  • In patients with XLRP, the EZ, a defined region within the photoreceptor layer of the retina, degenerates over time and is eventually lost.
  • AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases.

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Retrieved on: 
Monday, April 25, 2022
Clinical trial, Northwestern Health Sciences University, U.S. Securities and Exchange Commission, Security (finance), European Commission, Twitter, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Research, NR2E3, MD, Food, Science, Private Securities Litigation Reform Act, Retinitis pigmentosa, GLOBE, Doctor of Philosophy, Patient, LinkedIn, Retina, RHO, DSMB, Royal commission, Trial of the century, Review, Oregon Health & Science University, Vaccine, Company, Data monitoring committee, Drug discovery, SEC, Gene, Retinal degeneration, Safety, Hope, FDA, Health, Orphan drug, Pharmaceutical industry, Ophthalmology, Rhodopsin

The DSMB recommended that the Company continue enrolling the remaining study subjects in this current cohort at the target dose level.

Key Points: 
  • The DSMB recommended that the Company continue enrolling the remaining study subjects in this current cohort at the target dose level.
  • Traditional gene therapy, which transfers a functional version of a non-functional gene into target cells, addresses only one individual gene mutation at a time.
  • This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

Retrieved on: 
Tuesday, April 12, 2022
CEO, XV, Clinical trial, Northwestern Health Sciences University, HIV, U.S. Securities and Exchange Commission, Security (finance), Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SHIV, Food, Compliance, GLOBE, CCR5, Patient, Immunoglobulin G, 100,000, Form 10-K, Simian immunodeficiency virus, Infection, PLOS Pathogens, Oregon Health & Science University, Company, OTCQB, Vaccine, Social conditions in Honduras, Forward-looking statement, Optimism, Mab, Partnership, FDA, Cancer, Pharmaceutical industry, Leronlimab

The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.

Key Points: 
  • The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens.
  • These five participants came from an extension study, consisting of patients who were virologically suppressed in a prior study of leronlimab.
  • All five long-term participants successfully maintained HIV suppression via leronlimab monotherapy for over seven years, with no evidence of viral escape.
  • To monitor the anatomical penetrance of leronlimab, rhesus macaques acutely infected with simian human immunodeficiency virus (SHIV) were treated with high intravenous doses of leronlimab for 12 weeks.

AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Retrieved on: 
Monday, April 4, 2022
ARVO, Drug development, Retina, Northwestern Health Sciences University, Form 10-K, Therapy, Applied Genetic Technologies Corporation, Optogenetics, Forward-looking statement, AAV, Annual report, Oregon Health & Science University, Central nervous system, CNS, SEC, Doctor of Philosophy, Risk, Research, ACHM, Neurotology, Poster, Assistant, MD, Association for Research in Vision and Ophthalmology, Association, Technology, Nasdaq, COVID-19, GLOBE, Central nervous system disease, Patient, Pharmaceutical industry, Achromatopsia, Ophthalmology

We are excited to share these interim results from our ongoing gene therapy trials with members of the ophthalmology community, said Dr. Susan Schneider, Chief Medical Officer of AGTC.

Key Points: 
  • We are excited to share these interim results from our ongoing gene therapy trials with members of the ophthalmology community, said Dr. Susan Schneider, Chief Medical Officer of AGTC.
  • Over the past year, we have continued to validate the potential of our gene therapy platform with interim results from multiple clinical trials in XLRP and ACHM.
  • We anticipate that these findings will add to the growing body of evidence supporting our investigational treatments for those with rare inherited retinal diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3).